Aarhus University Seal

"Identifying biomarkers for diagnosis and treatment evaluation of Non-Alcoholic Fatty Liver Disease"

The oLIVER team identified potential biomarkers and drug targets for metabolic dysfunction-associated steatotic liver disease (MASLD) using a new approach called APTASHAPE. This approach uses billions of different small RNA biosensors to generate digital "fingerprint pictures" of blood plasma samples. As the oLIVER project focused on liver disease, the team compared samples from patients with samples from healthy controls. In this way, the oLIVER team identified discrete "fingerprint pictures" that are relevant for both diagnosis and prognosis of liver disease.

On this page you can can watch a video recorded at the beginning of the oLIVER project. You can also read an article on the output of the project or read a short cartoon story about the aim of the project.

"In a future collaboration with Novo Nordisk, the oLIVER team plans to investigate if (and how) the small RNA biosensor can also be used in the treatment of MASH.  Furthermore, the findings from the oLIVER project has given rise to plans about a spin-out company with the aim to further distribute the method in the Danish healthcare system."


Jørgen Kjems, Head of the oLIVER project


Academic team members

  • Jørgen Kjems, Professor, Aarhus University
  • Henning Grønbæk, Professor, Aaarhus University Hospital
  • Christian B. Vægter, Assoc. Professor, Aarhus University
  • Daniel Miotto Dupont
  • Søren Fjelstrup
  • Mikkel Breinholt Kjær
  • Asger Givskov Jørgensen

Industrial team member

  • Natasha Barascuk Michaelsen, Novo Nordisk 

"It has been a pleasure working with companies without first going through the standard legal tug-of-war. I definitely believe that the ability to talk openly and build on each others’ ideas have created a space where research is significantly accelerated. This is the background for the oLIVER project’s success."


Jørgen Kjems, Head of the oLIVER project


We unite right minds from industry and academia so that they can jointly create need-driven research projects - and pave the way for innovative new treatments in the future. Through competitive funding calls, we fund the best projects ideas. Although companies cannot receive funding, it is free of charge to join.

The 5-year platform is sponsored by the Novo Nordisk Foundation with 180 M DKK from 2024-2028.


You are always welcome to reach out if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.

Although we're spanning five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 121, blg 1521-216.